CompletedNot applicableNCT03412604

Effect of Modulating Gamma Oscillations Using tACS

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Massachusetts General Hospital
Principal Investigator
Emiliano Santarnecchi, PhD
Massachusetts General Hospital
Intervention
Transcranial Alternating Current Stimulation (tACS)(device)
Enrollment
5 target
Eligibility
45 years · All sexes
Timeline
20182019

Study locations (1)

Collaborators

Defense Advanced Research Projects Agency

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03412604 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials